Search Results

Keywords: epidiolex

Global Players Worth Watching

May 1, 2018

As more countries legalize medical and recreational cannabis, entrepreneurs are seizing the opportunity to become pioneers in the marijuana business.  From South America to Europe, India and Israel, companies are popping up to tackle cultivation and research, while others launch retail sales and ancillary businesses. Some companies with an established record in other industries are […]

Read More

Measure legalizing CBD medicine awaits OK from Colorado governor

April 25, 2018 · Updated April 7, 2020

The Colorado Legislature passed a bill that permits doctors to prescribe CBD medicines provided they have won approval from the U.S. Food and Drug Administration – a development that could happen within a matter of weeks. The state Senate signed off on the measure Tuesday, and it now moves to Gov. John Hicklenlooper for his signature. Passage […]

Read More

FDA advisory panel gives thumbs-up to CBD epilepsy treatment

April 19, 2018 · Updated February 18, 2019

A CBD treatment for epilepsy is closer to becoming the first cannabis medicine approved for the U.S. market. A panel of government health advisers gave a unanimous recommendation Thursday to the U.S. Food and Drug Administration to approve Epidiolex, a CBD medicine for rare epilepsy conditions that don’t respond to other drugs. The panel voted […]

Read More

Here’s how the FDA’s review of epilepsy drug could affect CBD companies

April 18, 2018 · Updated February 18, 2019

It’s shaping up to be a watershed summer for the cannabis industry with the U.S. Food and Drug Administration poised to approve the first drug made from the plant.

The agency’s impending decision on Epidiolex, an epilepsy treatment made of CBD extracted from cannabis flower, could upend decades of government insistence that the plant has no medicinal value.

Read More

Impending ruling on epilepsy drug has CBD industry on alert

April 11, 2018 · Updated February 18, 2019

The most disruptive product to hit the newly legal hemp industry might be one that will never be sold directly to consumers. GW Pharmaceuticals, a London-based biotech company, is awaiting a final decision from the U.S. Food and Drug Administration to produce the first cannabis-derived treatment to win approval as legal medicine. The decision on […]

Read More

GW Pharma aiming for FDA approval for CBD drug this year, again

January 26, 2018 · Updated July 16, 2018

British cannabis company GW Pharmaceuticals is hoping the U.S. Food and Drug Administration will sign off on its CBD-based epilepsy treatment, Epidiolex, as soon as this year. According to The Washington Post, GW is hoping to get the green light from the FDA to classify Epidiolex as a prescription drug, despite the fact it’s derived […]

Read More

FDA sends another round of warnings to CBD producers

November 1, 2017 · Updated July 16, 2018

Federal drug authorities have sent another round of warning letters to CBD producers about making health claims. The recipients include CW Hemp, the Colorado Springs, Colorado, company that supplies the popular Charlotte’s Web medicine for intractable epilepsy. The Food and Drug Administration sent four warning letters Wednesday to two Colorado companies – CW Hemp and Pueblo-based That’s Natural! […]

Read More

GW Pharma plans to expand marijuana operations in UK

August 29, 2017 · Updated August 15, 2019

One of the world’s biggest marijuanas companies – GW Phamaceuticals – is poised to get even bigger. The company announced that it’s planning an expansion in the United Kingdom, including the cultivation and processing of non-psychoactive cannabis, The Telegraph of London reported. GW Pharma’s plan stems from “anticipated demand” for a CBD-based drug, Sativex, designed […]

Read More

British Sugar to grow cannabis for GW Pharma

October 26, 2016 · Updated July 2, 2018

GW Pharmaceuticals, the British developer of a CBD-based anti-seizure medicine that could be on American shelves in 2018, has contracted Britain’s leading sugar supplier to grow its medical cannabis. British Sugar, the top beet sugar supplier in the UK, will grow the cannabis in an 18-hectare greenhouse in eastern England, where the company now grows tomatoes, […]

Read More

GW Pharma scuttles UK listing to trade on U.S. market

October 19, 2016 · Updated July 2, 2018

GW Pharmaceuticals, a high-flying biotech firm in the United Kingdom that is seeking U.S. regulatory approval for a CBD-based drug, has abandoned its U.K. stock market listing to instead trade exclusively in the United States. The firm announced it would ditch its Aim market listing this December, according to Britain’s Telegraph newspaper. A company executive […]

Read More